Welcome to our dedicated page for Fractyl Health SEC filings (Ticker: GUTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fractyl Health, Inc. (Nasdaq: GUTS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a publicly traded metabolic therapeutics biotechnology issuer. Fractyl Health files current reports on Form 8‑K, proxy materials, and registration‑related documents that describe its clinical progress, financing transactions, governance changes, and capital structure.
Investors can use these filings to track how Fractyl Health funds and advances its Revita® and Rejuva® programs in obesity and type 2 diabetes (T2D). Recent Forms 8‑K discuss underwritten offerings of common stock with Tranche A and Tranche B warrants, the terms of these securities, and subsequent actions such as the call of Tranche A warrants after specified clinical and trading performance conditions were achieved. Other 8‑K filings describe interim clinical data from the REMAIN‑1 Midpoint Cohort and REVEAL‑1, preclinical Rejuva results, and the company’s expectations for future clinical readouts and a potential PMA filing for Revita.
Fractyl Health’s proxy statement on Schedule DEF 14A and related meeting materials provide detail on special stockholder votes, including approvals tied to warrant exercisability under Nasdaq Listing Rule 5635(d). Additional filings cover board appointments, committee assignments, and director compensation, as well as quarterly results announcements furnished under Item 2.02 of Form 8‑K.
On Stock Titan, these SEC documents are complemented by AI‑powered tools that can help readers quickly interpret complex language in registration statements, financing agreements, and clinical data disclosures. Users can review real‑time updates from EDGAR, examine how warrant structures and equity offerings affect GUTS’s capital position, and locate information relevant to topics such as cash runway, study designs, and regulatory strategy, all within the context of Fractyl Health’s focus on metabolic therapeutics.
Fractyl Health (NASDAQ: GUTS) announced positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, showing promising results for weight management after GLP-1 discontinuation:
- 12 out of 13 participants maintained or lost weight after stopping GLP-1 treatment and receiving a single Revita procedure
- 6 participants achieved additional weight loss
- Median weight remained stable through 3 months, contrasting with typical 5-6% rebound in studies like SURMOUNT-4
- Procedure demonstrated strong safety profile with no serious adverse effects
Additionally, the company revealed new preclinical data for its Rejuva® Smart GLP-1™ pancreatic gene therapy platform. A single dose prevented obesity and hyperglycemia in animals on high-fat diets. The company expects REMAIN-1 Midpoint Cohort data in Q3 2025 and RJVA-001 preliminary clinical data in 2026.